There were no statistically significant differences in the odds of hypoglycaemia between most triple therapies; however, MET+ SU+ GLP-1-RA had reduced odds ratio for hypoglycaemia compared to MET+ SU+ insulin (odds ratio 0.44; 95% CI [0.25–0.76]) (Table 4). This evidence concerns the gene INS and Hypoglycemia.